The predictive value of serial bone scans in assessing response to chemotherapy in advanced breast cancer
- 1 April 1980
- Vol. 45 (7), 1562-1568
- https://doi.org/10.1002/1097-0142(19800401)45:7<1562::aid-cncr2820450709>3.0.co;2-g
Abstract
A retrospective analysis was made of 25 patients with breast cancer treated only with chemotherapy in order to determine the predictive value of technetium-99m bone scanning in determining response to chemotherapy. Whole-body scanning demonstrated bone healing in only 3 of 25 patients. However, the presence of stable disease on bone scan correlated with a good prognosis as 12 patients with stable scans had a significantly longer survival time than did the 13 patients who showed progression on scans (17.7 and 7.8 months, respectively P 0.005, Wilcoxan). Our analysis indicates that bone scans are a relatively crude technique for monitoring response to chemotherapy in patients with breast cancer.This publication has 11 references indexed in Scilit:
- A randomized comparative trial of adriamycin versus methotrexate in combination drug therapyCancer, 1978
- Serial Bone Scanning Using Technetium 99m Diphosphonate in Patients Undergoing Cyclical Combination Chemotherapy for Advanced Breast CancerClinical Nuclear Medicine, 1976
- Combination Chemotherapy for Advanced Breast Cancer: Response and Effect on SurvivalAnnals of Internal Medicine, 1976
- A controlled study in the use of combined drug therapy for metastatic breast cancerCancer, 1975
- The significance of occult skeletal metastases, detected by skeletal scintigraphy, in patients with otherwise apparently “early” mammary carcinomaBritish Journal of Surgery, 1975
- Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancerCancer, 1975
- The application of the 99Tcm phosphate bone scan to the study of breast cancerBritish Journal of Surgery, 1975
- Osseous Metastasis in Mammary CancerArchives of Surgery, 1970
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samplesBiometrika, 1965
- Combined estrogenic and androgenic hormone therapy in advanced breast cancerCancer, 1965